Skip to main content
TipRanks
Go Ultimate75% OFF

Ajanta Pharma Limited (AJANTPHARM) Stock Price & Analysis

6 Followers

AJANTPHARM Stock Chart & Stats

₹3,311.20-₹47.50(-1.41%)
At close: 3:30 PM GMT+5:30
₹3.25K₹3.5KAug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
INR 3,304.00 - INR 3,379.95
52-Week Range
INR 2,446.35 - INR 3,796.95
Previous Close
INR 3,358.70
Volume
N/A
Average Volume (3M)
20.01K
Market Cap
INR 413.76B
Enterprise Value
INR 447.23B
Total Cash (Recent Filing)
INR 6.80B
Total Debt (Recent Filing)
INR 1.54B
Price to Earnings (P/E)
32.8
Beta
0.19
Next Earnings
Feb 03, 2027 (Est.)
Dividend Yield
0.97%

Bulls Say, Bears Say

Bulls Say

Steady Growth And Profitability

Sustained revenue growth alongside historically strong net and operating margins indicates that Ajanta Pharma has maintained healthy commercial execution. This combination supports reinvestment, resilience across therapeutic areas, and the potential for earnings to compound over the next several quarters.

Conservative Balance Sheet

Low leverage gives Ajanta Pharma meaningful financial flexibility to fund operations, pursue growth, and absorb business volatility without excessive financing pressure. Consistently strong return on equity also indicates that the company has historically converted its capital base into profitable growth.

Diversified Specialty Portfolio

A broad prescription-led portfolio across several therapeutic areas and geographies reduces reliance on any single product category. Branded and generic formulations also provide multiple routes to market, supporting a more durable commercial base than a narrowly concentrated product portfolio.

Bears Say

FY2026 Margin Compression

The FY2026 margin decline indicates that recent revenue growth has not translated into equally stable profitability. If mix, pricing, or cost pressures persist, they could reduce operating leverage and limit the earnings benefit of continued sales expansion over the medium term.

Weaker Cash Conversion

Weaker conversion of accounting profit into operating cash reduces the predictability and flexibility of Ajanta Pharma’s financial performance. Working-capital swings or higher cash investment can constrain internally funded growth and make reported earnings less representative of available cash.

Debt Increased In FY2026

The FY2026 increase in debt is a developing balance-sheet watch point even though overall leverage remains low. Continued borrowing could gradually raise financing obligations and reduce the conservative financial flexibility that has supported the company’s historical resilience.

Ajanta Pharma Limited News

AJANTPHARM FAQ

What was Ajanta Pharma Limited’s price range in the past 12 months?
Ajanta Pharma Limited lowest stock price was ₹2446.35 and its highest was ₹3796.95 in the past 12 months.
What is Ajanta Pharma Limited’s market cap?
Ajanta Pharma Limited’s market cap is ₹413.76B.
When is Ajanta Pharma Limited’s upcoming earnings report date?
Ajanta Pharma Limited’s next earnings report is estimated for Feb 03, 2027 (not yet confirmed), which is in 76 days.
How were Ajanta Pharma Limited’s earnings last quarter?
Ajanta Pharma Limited released its earnings results on Oct 30, 2026. The company reported ₹31.03 earnings per share for the quarter, beating the consensus estimate of ₹25.129 by ₹5.901.
Is Ajanta Pharma Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Ajanta Pharma Limited pay dividends?
Ajanta Pharma Limited pays an annual dividend of ₹32 which represents an annual dividend yield of 0.97%. See more information on Ajanta Pharma Limited dividends here
What is Ajanta Pharma Limited’s EPS estimate?
Ajanta Pharma Limited’s EPS estimate is 23.70.
How many shares outstanding does Ajanta Pharma Limited have?
Ajanta Pharma Limited has 124,959,020 shares outstanding.
What happened to Ajanta Pharma Limited’s price movement after its last earnings report?
Ajanta Pharma Limited reported an EPS of ₹31.03 in its last earnings report, beating expectations of ₹25.129. Following the earnings report the stock price went up 1.519%.
Which hedge fund is a major shareholder of Ajanta Pharma Limited?
Currently, no hedge funds are holding shares in IN:AJANTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology